Sergey A. Krynskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergey A. Krynskiy has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Irina K. Malashenkova
National research center “Kurchatov Institute
11 shared publications - Daniil P. Ogurtsov
National research center “Kurchatov Institute
9 shared publications - Nikolay A. Didkovsky
Federal Research and Clinical Center of Physical-Chemical Medicine
9 shared publications - Nikita A. Khailov
National research center “Kurchatov Institute
7 shared publications - Vadim Leonidovich Ushakov
Lomonosov Moscow State University
7 shared publications - Ekaterina I. Chekulaeva
National research center “Kurchatov Institute
5 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 16 (1) , 128-140
An impact of latent toxoplasmosis reactivation on immune system and clinical dynamics in patients with mild cognitive impairment
Mild cognitive impairment (MCI) in a number of cases precedes the development of dementia. Neuroinflammation is one of the key factors in neurodegeneration pathogenesis. Chronic infections and parasitic infestations contribute significantly to neuroinflammation. It has been evident about a link between systemic inflammation, disorders of cellular and humoral immunity and MCI progression. In this context, of particular interest is a role for a common intracellular pathogen Toxoplasma gondii may be involved in MCI pathogenesis and clinical dynamics. Currently, the frequency and clinical significance of toxoplasmosis reactivation in MCI remain unknown. Given Toxoplasma gondii-related immunotropic effects, it is also relevant to investigate an association between latent toxoplasmosis reactivation, immune parameters and inflammatory mediators in MCI. The study was aimed at assessing the frequency of chronic toxoplasmosis reactivation and its associations with cell immunity, levels of main cytokines and chemokines along with clinical dynamics in MCI. For this, individuals were divided into the following groups: main group included 130 patients with MCI, and comparison group — 81 patients with subjective cognitive impairment (preMCI). The serum was tested for anti-Toxoplasma gondii IgG, IgM, and IgA antibodies using enzyme-linked immunosorbent assay, the concentration of cytokines and chemokines was determined by multiplex assay. Cell immunity was assessed using flow cytometry. The Kruskal–Wallis test was used to assess the significance of differences, followed by pairwise comparisons with Mann–Whitney test. An increased frequency of latent toxoplasmosis reactivation (positive for anti-Toxoplasma gondii IgA in combination with IgG 50 IU/mL) was observed in MCI. In MCI patients, reactivation of toxoplasmosis was associated with impaired activation of Th1-cell immunity (lower total and subset T-cell counts including CD4+CD57+ T-cells and CD8+CD57+ T-cells), as well as increased levels and activation of NK-cells. Higher anti-Toxoplasma gondii IgG level in patients was associated with elevated neuroinflammatory markers CCL4 and CCL20, and with less favorable one-year-follow-up clinical dynamics. The results suggest that reactivation of latent toxoplasmosis in MCI may be clinically relevant, and it is important to determine not only anti-Toxoplasma gondii IgG and IgM, but also IgA to detect it.
- 30 March 2026
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 16 (1) , 128-140
Open AccessAn impact of latent toxoplasmosis reactivation on immune system and clinical dynamics in patients with mild cognitive impairment
Mild cognitive impairment (MCI) in a number of cases precedes the development of dementia. Neuroinflammation is one of the key factors in neurodegeneration pathogenesis. Chronic infections and parasitic infestations contribute significantly to neuroinflammation. It has been evident about a link between systemic inflammation, disorders of cellular and humoral immunity and MCI progression. In this context, of particular interest is a role for a common intracellular pathogen Toxoplasma gondii may be involved in MCI pathogenesis and clinical dynamics. Currently, the frequency and clinical significance of toxoplasmosis reactivation in MCI remain unknown. Given Toxoplasma gondii-related immunotropic effects, it is also relevant to investigate an association between latent toxoplasmosis reactivation, immune parameters and inflammatory mediators in MCI. The study was aimed at assessing the frequency of chronic toxoplasmosis reactivation and its associations with cell immunity, levels of main cytokines and chemokines along with clinical dynamics in MCI. For this, individuals were divided into the following groups: main group included 130 patients with MCI, and comparison group — 81 patients with subjective cognitive impairment (preMCI). The serum was tested for anti-Toxoplasma gondii IgG, IgM, and IgA antibodies using enzyme-linked immunosorbent assay, the concentration of cytokines and chemokines was determined by multiplex assay. Cell immunity was assessed using flow cytometry. The Kruskal–Wallis test was used to assess the significance of differences, followed by pairwise comparisons with Mann–Whitney test. An increased frequency of latent toxoplasmosis reactivation (positive for anti-Toxoplasma gondii IgA in combination with IgG 50 IU/mL) was observed in MCI. In MCI patients, reactivation of toxoplasmosis was associated with impaired activation of Th1-cell immunity (lower total and subset T-cell counts including CD4+CD57+ T-cells and CD8+CD57+ T-cells), as well as increased levels and activation of NK-cells. Higher anti-Toxoplasma gondii IgG level in patients was associated with elevated neuroinflammatory markers CCL4 and CCL20, and with less favorable one-year-follow-up clinical dynamics. The results suggest that reactivation of latent toxoplasmosis in MCI may be clinically relevant, and it is important to determine not only anti-Toxoplasma gondii IgG and IgM, but also IgA to detect it.
- Open Access
- 25 November 2025
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (4) , 36-47
Clinical and Biological Significance of Neuroinflammation Indicators to Predict the Course of Amnestic Mild Cognitive Impairment
Background: neuroinfiammation which occurs as a long-term latent activation of systemic infiammation in the central nervous system is currently considered as one of the main pathogenetic mechanisms of the neurodegeneration progression in the brain of patients with Alzheimer’s disease. The aim of study is to research the prognostic significance of clinical and immunological parameters determined in the blood serum of patients with amnestic Mild Cognitive Impairment (aMCI) and to form an immunological profile that determines the further dynamics of the syndrome. Patients and Methods : 261 outpatient with aMCI were followed up at the FSBSI “Mental Health Research Centre” in the period from 2014 to 2023. The study participants underwent a general clinical examination and assessment of cognitive functions using a battery of psychometric tests and scales (MMSE, MoCA, CDT, tests of 10 words and 5 geometric shapes memorization, the Hachinski ischemic scale). In addition, patients underwent an initial level of cytokines study (TNFa, IL-1, IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10) in blood serum by enzyme immunoassay (ELISA); the levels of leukocyte elastase enzymatic activity (LE) and α1-proteinase inhibitor functional activity were determined in blood plazma by the spectrophotometric method. The protease inhibitory index was calculated. Conclusion: the cytokines set and immune response indicators have been identified. The distinguishing levels of TNFa, IL-6, IL-1b, LE predict various variants of three year course of aMCI including the conversion to dementia.
- 25 November 2025
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (4) , 36-47
Open AccessClinical and Biological Significance of Neuroinflammation Indicators to Predict the Course of Amnestic Mild Cognitive Impairment
Background: neuroinfiammation which occurs as a long-term latent activation of systemic infiammation in the central nervous system is currently considered as one of the main pathogenetic mechanisms of the neurodegeneration progression in the brain of patients with Alzheimer’s disease. The aim of study is to research the prognostic significance of clinical and immunological parameters determined in the blood serum of patients with amnestic Mild Cognitive Impairment (aMCI) and to form an immunological profile that determines the further dynamics of the syndrome. Patients and Methods : 261 outpatient with aMCI were followed up at the FSBSI “Mental Health Research Centre” in the period from 2014 to 2023. The study participants underwent a general clinical examination and assessment of cognitive functions using a battery of psychometric tests and scales (MMSE, MoCA, CDT, tests of 10 words and 5 geometric shapes memorization, the Hachinski ischemic scale). In addition, patients underwent an initial level of cytokines study (TNFa, IL-1, IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10) in blood serum by enzyme immunoassay (ELISA); the levels of leukocyte elastase enzymatic activity (LE) and α1-proteinase inhibitor functional activity were determined in blood plazma by the spectrophotometric method. The protease inhibitory index was calculated. Conclusion: the cytokines set and immune response indicators have been identified. The distinguishing levels of TNFa, IL-6, IL-1b, LE predict various variants of three year course of aMCI including the conversion to dementia.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (9) , 51-59
Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study
Objective. To study the efficacy and safety of long-term (3 years) course Cerebrolysin therapy in an open comparative study as a means potentially capable of slowing or preventing the transition of MCI into dementia, as well as to analyze the possibility of Cerebrolysin preventive effect predicting based on clinical and biological parameters. Material and methods. In total, 100 patients with aMCI were included in the study, randomly assigned to 2 groups: patients of group 1 (n=50) received annual course therapy with Cerebrolysin for 3 years (20 intravenous infusions of Cerebrolysin 20 ml in 100 ml of saline solution for 4 weeks). Group 2 patients underwent annual clinical examination, but did not receive therapy. All patients were monitored on an outpatient basis and were examined once a year. Clinical and psychopathological, psychometric, immunological, catamnestic, molecular genetic, and statistical methods were used. Results. A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy with Cerebrolysin and those who did not receive therapy showed a lower progression of cognitive deficits and a significantly lower conversion rate to dementia in patients who received annual courses for 3 years Cerebrolysin therapy compared with the comparison group. Conclusion. The data obtained indicate the presence of a disease-modifying effect in the annual course of Cerebrolysin and the possibility of using this drug in programs of dementia preventive therapy in people with a high risk of cognitive deficits progression and the dementia development in elderly patients with aMCI.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (9) , 51-59
Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study
Objective. To study the efficacy and safety of long-term (3 years) course Cerebrolysin therapy in an open comparative study as a means potentially capable of slowing or preventing the transition of MCI into dementia, as well as to analyze the possibility of Cerebrolysin preventive effect predicting based on clinical and biological parameters. Material and methods. In total, 100 patients with aMCI were included in the study, randomly assigned to 2 groups: patients of group 1 (n=50) received annual course therapy with Cerebrolysin for 3 years (20 intravenous infusions of Cerebrolysin 20 ml in 100 ml of saline solution for 4 weeks). Group 2 patients underwent annual clinical examination, but did not receive therapy. All patients were monitored on an outpatient basis and were examined once a year. Clinical and psychopathological, psychometric, immunological, catamnestic, molecular genetic, and statistical methods were used. Results. A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy with Cerebrolysin and those who did not receive therapy showed a lower progression of cognitive deficits and a significantly lower conversion rate to dementia in patients who received annual courses for 3 years Cerebrolysin therapy compared with the comparison group. Conclusion. The data obtained indicate the presence of a disease-modifying effect in the annual course of Cerebrolysin and the possibility of using this drug in programs of dementia preventive therapy in people with a high risk of cognitive deficits progression and the dementia development in elderly patients with aMCI.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (8) , 81-91
Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI
Objective. To study the relationship of the parameters of immunity and systemic inflammation with the structural magnetic resonance imaging (MRI) parameters in patients with mild cognitive impairment (MCI) and pre-MCI undergoing neurocognitive rehabilitation to search for candidate markers of its effectiveness. Material and methods. The main group included 49 patients, aged ≥60 years, with MCI and pre-MCI with memory impairment, who underwent a course of neurorehabilitation for 5 weeks. The control group included 19 volunteers of similar age with a total MoCA score of ≥25, who did not have cognitive impairment and immuno-inflammatory disorders. The parameters of cellular and humoral immunity and markers of inflammation were studied, and structural MRI was performed. Results. The content of activated natural killer cells (NK-cells) was increased in MCI and pre-MCI (0.63±0.12% vs. 0.22±0.07% in the control group, p=2.2·10–7). The level of immunoglobulin G (IgG) <12.5 g/l in patients with MCI and pre-MCI with the Montreal Cognitive Assessment Scale (MoCA) score <22 was associated with a decrease in the volume of the right nucleus accumbens (376±35 mm3 in patients with IgG <12.5 g/l (p=0.0013) and 480±44 mm3 at IgG <12.5 g/l, 480±44 mm3 in the control group), as well as with a decrease of the thickness and volume of a number of other cortical zones. A logistic regression model including the level of immunoglobulin G, NK cells, CD8+ NK cells and right amygdala volume was constructed to predict the number of MoCA scores 6 months after the course of rehabilitation (R2=0.57; p<1·10–5; standard error of estimate: 2.93). Conclusion. As a result of this work, the perspectives of assessing the immunological parameters in combination with socio-demographic data and morphometric changes of the brain as potential prognostic markers of the dynamics of cognitive impairment in patients with MCI and pre-MCI after neurorehabilitation has been shown.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (8) , 81-91
Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI
Objective. To study the relationship of the parameters of immunity and systemic inflammation with the structural magnetic resonance imaging (MRI) parameters in patients with mild cognitive impairment (MCI) and pre-MCI undergoing neurocognitive rehabilitation to search for candidate markers of its effectiveness. Material and methods. The main group included 49 patients, aged ≥60 years, with MCI and pre-MCI with memory impairment, who underwent a course of neurorehabilitation for 5 weeks. The control group included 19 volunteers of similar age with a total MoCA score of ≥25, who did not have cognitive impairment and immuno-inflammatory disorders. The parameters of cellular and humoral immunity and markers of inflammation were studied, and structural MRI was performed. Results. The content of activated natural killer cells (NK-cells) was increased in MCI and pre-MCI (0.63±0.12% vs. 0.22±0.07% in the control group, p=2.2·10–7). The level of immunoglobulin G (IgG) <12.5 g/l in patients with MCI and pre-MCI with the Montreal Cognitive Assessment Scale (MoCA) score <22 was associated with a decrease in the volume of the right nucleus accumbens (376±35 mm3 in patients with IgG <12.5 g/l (p=0.0013) and 480±44 mm3 at IgG <12.5 g/l, 480±44 mm3 in the control group), as well as with a decrease of the thickness and volume of a number of other cortical zones. A logistic regression model including the level of immunoglobulin G, NK cells, CD8+ NK cells and right amygdala volume was constructed to predict the number of MoCA scores 6 months after the course of rehabilitation (R2=0.57; p<1·10–5; standard error of estimate: 2.93). Conclusion. As a result of this work, the perspectives of assessing the immunological parameters in combination with socio-demographic data and morphometric changes of the brain as potential prognostic markers of the dynamics of cognitive impairment in patients with MCI and pre-MCI after neurorehabilitation has been shown.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 92-99
Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study
OBJECTIVE To study the efficacy and safety of the use of annual course therapy of choline alfoscerate (CA) as a drug potentially capable of slowing or preventing the transition of amnesic type mild cognitive impairment (aMCI) into clinically pronounced dementia in a three-year open comparative study, as well as to explore the possibility of predicting the preventive effect of such therapy based on a number of clinical and biological parameters. MATERIAL AND METHODS The study included 100 patients with aMCI, randomly divided into 2 groups: the therapeutic group consisted of 50 patients who received CA course therapy once a year for 3 years (20 intravenous infusions of 1000 mg (4 ml) in 100 ml of saline solution for 4 weeks) and a comparison group of 50 patients who underwent an annual examination at the center and did not receive therapy. Clinical and psychopathological, psychometric, immunological, follow-up, and statistical methods were used. RESULTS A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy of CA for 3 years and aMCI patients who did not receive therapy with similar initial demographic, diagnostic, psychometric and immunological characteristics showed a lower progression of cognitive deficits (12.2% and 39.1%, respectively) and a lower conversion rate (8.2% and 26.1%, respectively) to dementia in the therapeutic group compared with the comparison group. The differences between the initial and final (after 1, 2 and 3 years of follow-up) cognitive functioning indicators in the therapeutic group and the comparison group were significant (p<0.05) on all scales and tests in favor of the therapeutic group throughout the entire follow-up period. CONCLUSION The results allow us to consider CA as a possible model of preventive dementia therapy aimed at preventing the progression of cognitive deficits and the development of dementia in people at high risk of developing AD — patients with aMCI.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 92-99
Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study
OBJECTIVE To study the efficacy and safety of the use of annual course therapy of choline alfoscerate (CA) as a drug potentially capable of slowing or preventing the transition of amnesic type mild cognitive impairment (aMCI) into clinically pronounced dementia in a three-year open comparative study, as well as to explore the possibility of predicting the preventive effect of such therapy based on a number of clinical and biological parameters. MATERIAL AND METHODS The study included 100 patients with aMCI, randomly divided into 2 groups: the therapeutic group consisted of 50 patients who received CA course therapy once a year for 3 years (20 intravenous infusions of 1000 mg (4 ml) in 100 ml of saline solution for 4 weeks) and a comparison group of 50 patients who underwent an annual examination at the center and did not receive therapy. Clinical and psychopathological, psychometric, immunological, follow-up, and statistical methods were used. RESULTS A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy of CA for 3 years and aMCI patients who did not receive therapy with similar initial demographic, diagnostic, psychometric and immunological characteristics showed a lower progression of cognitive deficits (12.2% and 39.1%, respectively) and a lower conversion rate (8.2% and 26.1%, respectively) to dementia in the therapeutic group compared with the comparison group. The differences between the initial and final (after 1, 2 and 3 years of follow-up) cognitive functioning indicators in the therapeutic group and the comparison group were significant (p<0.05) on all scales and tests in favor of the therapeutic group throughout the entire follow-up period. CONCLUSION The results allow us to consider CA as a possible model of preventive dementia therapy aimed at preventing the progression of cognitive deficits and the development of dementia in people at high risk of developing AD — patients with aMCI.
- 14 February 2024
- Published by Springer Nature
- p. 577-587
Polymorphisms of IL10 Immunoregulatory Gene Impact the Morphometric Changes of the Brain in Schizophrenia
- 14 February 2024
- Published by Springer Nature
- p. 577-587
Polymorphisms of IL10 Immunoregulatory Gene Impact the Morphometric Changes of the Brain in Schizophrenia
- Open Access
- 1 June 2023
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 25 (5) , 1225-1232
Associations of IL17A G-197A single nucleotide polymorphism with immunological parameters and structural changes of the brain in schizophrenia
Schizophrenia is a chronic mental disorder that is caused by a complex palette of genetic, epigenetic and environmental factors. Some of the important components of its pathogenesis are systemic inflammation and the dysfunction of immunity, which lead to neuroinflammation, contributing to development of structural brain changes. Earlier we have shown that increase in interleukin-17A levels is associated with morphometric changes and immune dysregulation in schizophrenia. IL17A G-197A (rs2275913) genetic polymorphism is involved in determining interleukin-17A secretion. The goal of this work was to investigate the associations between rs2275913 polymorphism, immune disorders and structural neurovisualization findings in schizophrenia to provide new insights into the immunopathogenesis of this disease. 60 patients aged 18 to 42 years diagnosed with schizophrenia were enrolled. 85 healthy volunteers were included into the control group. Multiplex assay was used to determine cytokine and chemokine serum levels. Rs2275913 polymorphism was assessed by polymerase chain reaction with electrophoretic detection of amplification products. A number of relationships between rs2275913 polymorphism and the immune parameters in schizophrenia were revealed. Carriers of G allele showed significant increase in IFNY, a key cytokine of Th1-link of adaptive immunity, and IL-8, an inflammatory chemokine. Also, increased levels of CXCL16 were observed in patients carrying the G allele. CXCL16 activates secretion of other proinflammatory chemokines and is involved in activation of Th1 adaptive immunity. Associations of heterozygous GA genotype with reduced cortical thickness in a number of areas of the frontal cortex in schizophrenia were found. Changes in cortical thickness in some of these areas, including middle frontal gyrus and orbitofrontal cortex, can be relevant to the pathogenesis of schizophrenia. The results highlight the importance of immunogenetic factors in the pathogenesis of schizophrenia and indicate that the rs2275913 polymorphism requires further studies as a potential biomarker of immune dysregulation and morphometric brain changes in schizophrenia.
- 1 June 2023
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 25 (5) , 1225-1232
Open AccessAssociations of IL17A G-197A single nucleotide polymorphism with immunological parameters and structural changes of the brain in schizophrenia
Schizophrenia is a chronic mental disorder that is caused by a complex palette of genetic, epigenetic and environmental factors. Some of the important components of its pathogenesis are systemic inflammation and the dysfunction of immunity, which lead to neuroinflammation, contributing to development of structural brain changes. Earlier we have shown that increase in interleukin-17A levels is associated with morphometric changes and immune dysregulation in schizophrenia. IL17A G-197A (rs2275913) genetic polymorphism is involved in determining interleukin-17A secretion. The goal of this work was to investigate the associations between rs2275913 polymorphism, immune disorders and structural neurovisualization findings in schizophrenia to provide new insights into the immunopathogenesis of this disease. 60 patients aged 18 to 42 years diagnosed with schizophrenia were enrolled. 85 healthy volunteers were included into the control group. Multiplex assay was used to determine cytokine and chemokine serum levels. Rs2275913 polymorphism was assessed by polymerase chain reaction with electrophoretic detection of amplification products. A number of relationships between rs2275913 polymorphism and the immune parameters in schizophrenia were revealed. Carriers of G allele showed significant increase in IFNY, a key cytokine of Th1-link of adaptive immunity, and IL-8, an inflammatory chemokine. Also, increased levels of CXCL16 were observed in patients carrying the G allele. CXCL16 activates secretion of other proinflammatory chemokines and is involved in activation of Th1 adaptive immunity. Associations of heterozygous GA genotype with reduced cortical thickness in a number of areas of the frontal cortex in schizophrenia were found. Changes in cortical thickness in some of these areas, including middle frontal gyrus and orbitofrontal cortex, can be relevant to the pathogenesis of schizophrenia. The results highlight the importance of immunogenetic factors in the pathogenesis of schizophrenia and indicate that the rs2275913 polymorphism requires further studies as a potential biomarker of immune dysregulation and morphometric brain changes in schizophrenia.
- Open Access
- 1 June 2023
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 25 (5) , 1233-1240
Levels of chemokines and other inflammatory mediators in patients with mild cognitive impairment undergoing rehabilitation
Alzheimer's disease is the most common neurodegenerative disease in old age. In some cases, it is preceded by mild cognitive impairment (MCI). One of the important components in the pathogenesis of neurodegeneration is chronic neuroinflammation (inflammatory activation of microglia and astrocytes in the brain). Systemic inflammatory response and immune dysregulation may contribute to neuroinflammation. The purpose of this study was to investigate the level of chemokines and other inflammatory mediators in patients with MCI who underwent medical rehabilitation, and to study its associations with the severity of cognitive impairment. The study group included 48 patients with MCI undergoing rehabilitation. Rehabilitation included cognitive therapy, psychotherapy and tasks for unaided performance. Repeated examination was conducted 6 months after the completion of rehabilitation. The control group included 46 healthy volunteers. Multiplex assay was used to determine serum cytokine and chemokine concentrations. Student's t-test was used to assess the significance of differences. Assessment of cognitive functions was performed using international neuropsychological scales. In patients with MCI, we have found an increase in the levels of several cytokines and chemokines (TNFα, CXCL10/IP10, MDC) that regulate systemic inflammation, cellular and humoral mechanisms of adaptive immunity. After the rehabilitation course their levels returned to normal. It was also found that decrease in CCL7 level in the patients before the rehabilitation course is associated with the severity of cognitive impairment. The findings contribute to understanding the role of chemokines in the pathogenesis of MCI, and indicate that their levels can be potential biomarkers of the severity of cognitive impairment. For translation of the findings into clinical practice, their validation in larger studies is needed, as well as assessing the associations between chemokine levels and the severity of cognitive impairment in MCI over long-term follow-up.
- 1 June 2023
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 25 (5) , 1233-1240
Open AccessLevels of chemokines and other inflammatory mediators in patients with mild cognitive impairment undergoing rehabilitation
Alzheimer's disease is the most common neurodegenerative disease in old age. In some cases, it is preceded by mild cognitive impairment (MCI). One of the important components in the pathogenesis of neurodegeneration is chronic neuroinflammation (inflammatory activation of microglia and astrocytes in the brain). Systemic inflammatory response and immune dysregulation may contribute to neuroinflammation. The purpose of this study was to investigate the level of chemokines and other inflammatory mediators in patients with MCI who underwent medical rehabilitation, and to study its associations with the severity of cognitive impairment. The study group included 48 patients with MCI undergoing rehabilitation. Rehabilitation included cognitive therapy, psychotherapy and tasks for unaided performance. Repeated examination was conducted 6 months after the completion of rehabilitation. The control group included 46 healthy volunteers. Multiplex assay was used to determine serum cytokine and chemokine concentrations. Student's t-test was used to assess the significance of differences. Assessment of cognitive functions was performed using international neuropsychological scales. In patients with MCI, we have found an increase in the levels of several cytokines and chemokines (TNFα, CXCL10/IP10, MDC) that regulate systemic inflammation, cellular and humoral mechanisms of adaptive immunity. After the rehabilitation course their levels returned to normal. It was also found that decrease in CCL7 level in the patients before the rehabilitation course is associated with the severity of cognitive impairment. The findings contribute to understanding the role of chemokines in the pathogenesis of MCI, and indicate that their levels can be potential biomarkers of the severity of cognitive impairment. For translation of the findings into clinical practice, their validation in larger studies is needed, as well as assessing the associations between chemokine levels and the severity of cognitive impairment in MCI over long-term follow-up.
- Open Access
- 8 December 2022
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 24 (6) , 1159-1170
Association of IL-17A levels with immuneinflammatory profile and structural MRI data in patients with schizophrenia
IL-17A is a proinflammatory cytokine involved in pathogenesis of some neuroinflammatory diseases of the brain. However, its role in schizophrenia is poorly understood. Currently, noninvasive neuroimaging techniques are widely used to assess abnormalities in brain morphology and interactions of neuronal networks in schizophrenia. The aim of this work was to study associations between IL-17A level and brain morphometric parameters in schizophrenia, in order to clarify immune factors of pathogenesis and search for biomarkers of unfavorable disease course. 45 patients with schizophrenia and 30 healthy volunteers were included into the study. The levels of cytokines (IL-5, IL-6, IL-8, IL-10, IL-17A) and inflammatory markers were determined by ELISA or multiplex analysis. MRI scans were performed with a Siemens Magnetom Verio 3T MRI scanner. We used Kruskal–Wallis test to assess significant differences in immunological parameters followed by Mann–Whitney paired comparison; Student test to assess the significance of differences in morphometric parameters of the brain; Fisher exact test to assess the differences in discrete variables, with the differences considered statistically significant at p < 0.05. IL-17A levels were found to be increased in schizophrenia. Its elevated content was associated with increased levels of C-reactive protein, IL-5, IL-6, IL-8, IL-10, and the presence of morphometric changes of frontal and temporal cortex in the patients. So far, the relationships between IL-17A levels, immunoinflammatory parameters and structural brain changes have not been studied in schizophrenia. In the present work, we found an association of elevated IL-17A levels with decreased cortical thickness in several brain regions, systemic inflammation and activation of Th2-link of adaptive immunity in the patients with schizophrenia. According to the literature, a number of brain areas, where cortical thickness was associated with IL-17A levels may be relevant to pathogenesis of the disease and, in particular, to the development of negative symptoms, including impoverishment of interests, speech, and emotions. The results are important for understanding the role of immune disorders in pathogenesis of schizophrenia, including structural changes of the brain, and suggest that IL-17A may be a biomarker of these disorders. Confirmation of associations between structural neuroimaging findings, laboratory markers of inflammation and immune disorders may provide the basis for new multidisciplinary approaches to the diagnosis and prognosis of schizophrenia.
- 8 December 2022
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 24 (6) , 1159-1170
Open AccessAssociation of IL-17A levels with immuneinflammatory profile and structural MRI data in patients with schizophrenia
IL-17A is a proinflammatory cytokine involved in pathogenesis of some neuroinflammatory diseases of the brain. However, its role in schizophrenia is poorly understood. Currently, noninvasive neuroimaging techniques are widely used to assess abnormalities in brain morphology and interactions of neuronal networks in schizophrenia. The aim of this work was to study associations between IL-17A level and brain morphometric parameters in schizophrenia, in order to clarify immune factors of pathogenesis and search for biomarkers of unfavorable disease course. 45 patients with schizophrenia and 30 healthy volunteers were included into the study. The levels of cytokines (IL-5, IL-6, IL-8, IL-10, IL-17A) and inflammatory markers were determined by ELISA or multiplex analysis. MRI scans were performed with a Siemens Magnetom Verio 3T MRI scanner. We used Kruskal–Wallis test to assess significant differences in immunological parameters followed by Mann–Whitney paired comparison; Student test to assess the significance of differences in morphometric parameters of the brain; Fisher exact test to assess the differences in discrete variables, with the differences considered statistically significant at p < 0.05. IL-17A levels were found to be increased in schizophrenia. Its elevated content was associated with increased levels of C-reactive protein, IL-5, IL-6, IL-8, IL-10, and the presence of morphometric changes of frontal and temporal cortex in the patients. So far, the relationships between IL-17A levels, immunoinflammatory parameters and structural brain changes have not been studied in schizophrenia. In the present work, we found an association of elevated IL-17A levels with decreased cortical thickness in several brain regions, systemic inflammation and activation of Th2-link of adaptive immunity in the patients with schizophrenia. According to the literature, a number of brain areas, where cortical thickness was associated with IL-17A levels may be relevant to pathogenesis of the disease and, in particular, to the development of negative symptoms, including impoverishment of interests, speech, and emotions. The results are important for understanding the role of immune disorders in pathogenesis of schizophrenia, including structural changes of the brain, and suggest that IL-17A may be a biomarker of these disorders. Confirmation of associations between structural neuroimaging findings, laboratory markers of inflammation and immune disorders may provide the basis for new multidisciplinary approaches to the diagnosis and prognosis of schizophrenia.